NCT05117476 - A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors | Biotech Hunter

Enrollment

440

Participants

Timeline

Start Date

October 29, 2021

Primary Completion Date

March 31, 2026

Study Completion Date

June 30, 2026

Conditions

Advanced Solid TumorNSCLC

Interventions

DRUG

CLN-619

Anti-MICA/MICB monoclonal antibody

DRUG

Pembrolizumab

Keytruda

DRUG

Paclitaxel

Taxane

DRUG

Carboplatin AUC 6

Platinum compound

DRUG

pemetrexed

antifolate

DRUG

Datopotamab deruxtecan-dlnk (Dato-DXd)

TROP-2 antibody-drug conjugate (ADC)

Trial Locations (23)

3004

COMPLETED

Alfred Health, Melbourne

3168

COMPLETED

Monash Health, Clayton

6009

COMPLETED

Linear Clinical Research, Nedlands

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

22031

RECRUITING

Virginia Cancer Center, Fairfax

28040

RECRUITING

START Madrid FJD, Madrid

28078

COMPLETED

Carolina BioOncology Institute, Huntersville

31008

RECRUITING

Clinica Universidad de Navarra, Pamplona

34232

RECRUITING

Florida Cancer Specialists, Sarasota

35233

RECRUITING

University of Alabama at Birmingham, Birmingham

37203

RECRUITING

Sarah Cannon Research Institute, Nashville

49546

RECRUITING

START Midwest, Grand Rapids

78229

RECRUITING

START San Antonio, San Antonio

91010

RECRUITING

City of Hope, Duarte

92618

RECRUITING

City of Hope, Irvine

02215

COMPLETED

Dana-Farber Cancer Institute, Boston

07601

RECRUITING

Hackensack Meridian Health, Hackensack

05-410

COMPLETED

Biokinetica, Józefów

60-693

COMPLETED

Med-Polonia Sp. zo. o., Poznan

02-781

ACTIVE_NOT_RECRUITING

Narodowy Insytut Onkologii im Marii Sklodowskiej-Curie, Warsaw

08023

RECRUITING

START Barcelona, Barcelona

08036

COMPLETED

Hospital Clinic Barcelona, Barcelona

08208

COMPLETED

Hospital Universitari Parc Tauli, Sabadell